BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2023 10:42:35 AM | Browse: 148 | Download: 217
 |
Received |
|
2023-04-13 09:12 |
|
Peer-Review Started |
|
2023-04-13 09:15 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-07-04 08:24 |
|
Revised |
|
2023-07-05 22:51 |
|
Second Decision |
|
2023-07-21 02:49 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-07-24 00:54 |
|
Articles in Press |
|
2023-07-24 00:54 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-09-11 13:26 |
|
Publish the Manuscript Online |
|
2023-09-15 10:42 |
| ISSN |
2220-315x (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Critical Care Medicine |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Update on hydroxychloroquine use in pregnancy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Wassan Nori, Nabeeha Najatee Akram and Raid M Al-Ani |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wassan Nori, PhD, Academic Editor, Academic Research, Senior Researcher, Department of Obstetrics and Gynecology, Mustansiriyah University, No. 58 Al-amin Street, Baghdad 10052, Iraq. dr.wassan76@uomustansiriyah.edu.iq |
| Key Words |
Pregnancy; Hydroxychloroquine; Preeclampsia; Antiphospholipid syndrome; Chronic placental inflammation; COVID-19 |
| Core Tip |
The immunomodulatory, anti-inflammatory, and anti-thrombotic activity of hydroxychloroquine (HCQ), an anti-malarial drug, made it recommendable for rheumatoid arthritis and systemic lupus erythematosus. HCQ was also implemented in refractory antiphospholipid syndrome showing a successful outcome. Recent evidence supports the benefits of its use to outweigh the risk during pregnancy as it reduces the disease activity and the associated adverse pregnancy outcome. Chronic placental inflammation is another condition for which HCQ proved to be helpful. Further investigations are required to verify HCQ’s efficacy in chronic placental inflammation as well as its action in reducing the severity of coronavirus disease 2019 in pregnant women. |
| Publish Date |
2023-09-15 10:42 |
| Citation |
Nori W, Akram NN, Al-Ani RM. Update on hydroxychloroquine use in pregnancy. World J Exp Med 2023; 13(4): 99-101 |
| URL |
https://www.wjgnet.com/2220-315x/full/v13/i4/99.htm |
| DOI |
https://dx.doi.org/10.5493/wjem.v13.i4.99 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
